196 related articles for article (PubMed ID: 25444993)
1. Repair mechanisms help glioblastoma resist treatment.
Atkins RJ; Ng W; Stylli SS; Hovens CM; Kaye AH
J Clin Neurosci; 2015 Jan; 22(1):14-20. PubMed ID: 25444993
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
Johannessen TC; Bjerkvig R
Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
[TBL] [Abstract][Full Text] [Related]
3. Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide.
Thon N; Eigenbrod S; Grasbon-Frodl EM; Lutz J; Kreth S; Popperl G; Belka C; Kretzschmar HA; Tonn JC; Kreth FW
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):441-6. PubMed ID: 20861061
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
5. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
Balvers RK; Lamfers ML; Kloezeman JJ; Kleijn A; Berghauser Pont LM; Dirven CM; Leenstra S
J Transl Med; 2015 Feb; 13():74. PubMed ID: 25886061
[TBL] [Abstract][Full Text] [Related]
6. [MGMT and temozolomide sensibility].
Tabouret E
Bull Cancer; 2021 Dec; 108(12):1075-1076. PubMed ID: 34782119
[No Abstract] [Full Text] [Related]
7. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
8. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
9. High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Onishi S; Muragaki Y; Kawamata T; Kurisu K
World Neurosurg; 2017 Sep; 105():282-288. PubMed ID: 28602885
[TBL] [Abstract][Full Text] [Related]
10. One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?
Heiland DH; Haaker G; Watzlawick R; Delev D; Masalha W; Franco P; Machein M; Staszewski O; Oelhke O; Nicolay NH; Schnell O
J Neurooncol; 2018 Nov; 140(2):385-391. PubMed ID: 30076585
[TBL] [Abstract][Full Text] [Related]
11. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Fabi A; Russillo M; Metro G; Vidiri A; Di Giovanni S; Cognetti F
Anticancer Res; 2009 Jul; 29(7):2607-10. PubMed ID: 19596935
[TBL] [Abstract][Full Text] [Related]
12. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
15. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
16. Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study.
Franceschi E; Depenni R; Paccapelo A; Ermani M; Faedi M; Sturiale C; Michiara M; Servadei F; Pavesi G; Urbini B; Pisanello A; Crisi G; Cavallo MA; Dazzi C; Biasini C; Bertolini F; Mucciarini C; Pasini G; Baruzzi A; Brandes AA;
J Neurooncol; 2016 May; 128(1):157-162. PubMed ID: 26943851
[TBL] [Abstract][Full Text] [Related]
17. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
18. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
[TBL] [Abstract][Full Text] [Related]
19. MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT.
Nie E; Jin X; Wu W; Yu T; Zhou X; Shi Z; Zhang J; Liu N; You Y
J Neurooncol; 2017 May; 133(1):59-68. PubMed ID: 28425046
[TBL] [Abstract][Full Text] [Related]
20. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.
Wiewrodt D; Nagel G; Dreimüller N; Hundsberger T; Perneczky A; Kaina B
Int J Cancer; 2008 Mar; 122(6):1391-9. PubMed ID: 18000822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]